These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. Ferretti F; Cannatelli R; Benucci M; Carmagnola S; Clementi E; Danelli P; Dilillo D; Fiorina P; Galli M; Gallieni M; Genovese G; Giorgi V; Invernizzi A; Maconi G; Maier JA; Marzano AV; Morpurgo PS; Nebuloni M; Radovanovic D; Riva A; Rizzardini G; Sabiu G; Santus P; Staurenghi G; Zuccotti G; Sarzi-Puttini PC; Ardizzone S Front Immunol; 2021; 12():656362. PubMed ID: 33936084 [TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. Firinu D; Perra A; Campagna M; Littera R; Fenu G; Meloni F; Cipri S; Sedda F; Conti M; Miglianti M; Costanzo G; Secci M; Usai G; Carta MG; Cappai R; Orrù G; Del Giacco S; Coghe F; Chessa L Clin Exp Med; 2022 Aug; 22(3):477-485. PubMed ID: 34741188 [TBL] [Abstract][Full Text] [Related]
28. Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection by Type and Frequency of Vaccine: A Community-Based Case-Control Study. Gim H; Seo H; Chun BC J Korean Med Sci; 2024 Jun; 39(21):e174. PubMed ID: 38832478 [TBL] [Abstract][Full Text] [Related]
29. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study. Esquivel-Valerio JA; Skinner-Taylor CM; Moreno-Arquieta IA; Cardenas-de la Garza JA; Garcia-Arellano G; Gonzalez-Garcia PL; Almaraz-Juarez FDR; Galarza-Delgado DA Rheumatol Int; 2021 Dec; 41(12):2105-2108. PubMed ID: 34622311 [TBL] [Abstract][Full Text] [Related]
30. Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy. Caldera F; Rolak S; Farraye FA; Necela BM; Cogen D; Zona EE; Schell TL; Ramirez OR; Almasry M; Chun K; Hayney MS; Knutson KL Clin Transl Gastroenterol; 2024 Apr; 15(4):e00688. PubMed ID: 38349178 [TBL] [Abstract][Full Text] [Related]